{
  "ticker": "BMY",
  "company_name": "Bristol Myers Squibb",
  "summary": "Item 1. Business 1 Acquisitions, Divestitures, Licensing and Other Arrangements 2 Products, Intellectual Property and Product Exclusivity 2 Research and Development 8 Alliances 14 Marketing, Distribution and Customers 14 Competition 15 Pricing, Price Constraints and Market Access 16 Government Regulation 17 Sources and Availability of Raw Materials 20 Manufacturing and Quality Assurance 20 Environmental Regulation 21 Human Capital Management and Resources 21 Foreign Operations 22 Bristol Myers Squibb Website 22 Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi..."
}